These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 9272132)

  • 1. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
    Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
    Tobita T; Takeshita A; Kitamura K; Ohnishi K; Yanagi M; Hiraoka A; Karasuno T; Takeuchi M; Miyawaki S; Ueda R; Naoe T; Ohno R
    Blood; 1997 Aug; 90(3):967-73. PubMed ID: 9242525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
    Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Harada M; Ueda R; Ohno R
    Leuk Lymphoma; 1998 Nov; 31(5-6):441-51. PubMed ID: 9922035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
    Ohnishi K
    Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
    Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
    Guo W; Wang H; Zhao W
    Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
    Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
    Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
    Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
    Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells.
    Kitamura K; Yoshida H; Ohno R; Naoe T
    Int J Hematol; 1997 Feb; 65(2):179-85. PubMed ID: 9071824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
    Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
    Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    Liu P; Han ZC
    Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
    Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
    Tomita A; Kiyoi H; Naoe T
    Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia.
    Habib A; Hamade E; Mahfouz R; Nasrallah MS; de Thé H; Bazarbachi A
    Leukemia; 2008 Jun; 22(6):1125-30. PubMed ID: 18354491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
    Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
    Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
    Zhu Q; Zhang JW; Zhu HQ; Shen YL; Flexor M; Jia PM; Yu Y; Cai X; Waxman S; Lanotte M; Chen SJ; Chen Z; Tong JH
    Blood; 2002 Feb; 99(3):1014-22. PubMed ID: 11807007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
    Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
    Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
    Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.